The completion of enrollment and the start of dosing for the sixth dose cohort in the Phase 1/2 study of ONCT-534 is a significant milestone for Oncternal Therapeutics. The approval of a higher dose by the Safety Review Committee indicates positive safety data from the 600 mg cohort. Investors may view this progress favorably, potentially leading to a short-term increase in the stock price. The anticipated safety and efficacy update in Q3 2024 will be a critical event for the company's future prospects.